Company Description
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum.
The company also offers delivery models that include full service, functional service provider, and hybrid service structures.
In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services.
Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines.
Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16,120 |
| CEO | Peter Neupert |
Contact Details
Address: 8 Moore Drive Durham, North Carolina 27709 United States | |
| Phone | 877 495 0816 |
| Website | fortrea.com |
Stock Details
| Ticker Symbol | FTRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001965040 |
| CUSIP Number | 34965K107 |
| ISIN Number | US34965K1079 |
| Employer ID | 92-2796441 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Jill McConnell | Chief Financial Officer |
| Mark A. Morais | Chief Operating Officer and President of Clinical Services |
| Drayton Virkler | President and Chief Commercial Officer |
| Robert Parks | Chief Accounting Officer |
| Alejandro Martinez Galindo | Chief Information Officer |
| Dave Cooper | Chief Administrative Officer |
| Tracy H. Krumme | Senior Vice President of Investor Relations |
| J. Stillman Hanson J.D. | General Counsel and Corporate Secretary |
| Hima B. Inguva | Head of Corporate Development |
| Dr. Oren J. Cohen M.D. | Chief Medical Officer and President of Clinical Pharmacology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 6, 2025 | 10-Q | Quarterly Report |
| Aug 6, 2025 | SCHEDULE 13G/A | Filing |
| Aug 6, 2025 | 8-K | Current Report |
| Aug 5, 2025 | SCHEDULE 13G/A | Filing |
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |
| Jul 17, 2025 | SCHEDULE 13G/A | Filing |
| Jul 15, 2025 | SCHEDULE 13G/A | Filing |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-A12B | Registration of securities |
| Jun 12, 2025 | 8-K | Current Report |